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Abstract
It has long been recognized that a small animal model susceptible to HIV-1 infection with a
functional immune system would be extremely useful in the study of HIV/AIDS pathogenesis and
for the evaluation of vaccine and therapeutic strategies to combat this disease. By early 2007, a
number of reports on various rodent models capable of being infected by and responding to HIV
including some with a humanized immune system were published. The New Humanized Rodent
Model Workshop, organized by the Division of AIDS (DAIDS), National Institute Allergy and
Infection Diseases (NIAID), NIH, was held on September 24, 2007 at Bethesda for the purpose of
bringing together key model developers and potential users. This report provides a synopsis of the
presentations that discusses the current status of development and use of rodent models to
evaluate the pathogenesis of HIV infection and to assess the efficacy of vaccine and therapeutic
strategies including microbicides to prevent and/or treat HIVinfection.
Introduction
Investigation of many aspects of the in vivo behavior of
HIV as well as testing of the in vivo efficacy of novel anti-
HIV therapies and vaccines has been hampered by the
restriction of HIV infection to humans and primates [1].
Mice cannot be infected with HIV-1, because sequence dif-
ferences in mouse homologues of the human proteins
required for HIV replication prevent their interaction with
essential HIV proteins critical for HIV replication such as
Env, Tat [2,3] and Rev [3,4], as well as prevent and poten-
tially limit efficient assembly and budding of virus from
the cell membrane. These genetic differences result in
blocks at several stages of HIV replication that prevents
cellular infection and efficient production of HIV-1 by
mouse cells.
It has long been recognized that a small animal model
with a reconstituted human immune system would be
extremely useful in the study of HIV/AIDS pathogenesis
and for the evaluation of vaccine and therapeutic strate-
gies to combat this disease. By early 2007, a number of
reports on rodent models with a humanized immune sys-
tem capable of being infected by and responding to HIV
were published. The New Humanized Rodent Model
Workshop, organized by Janet Young, Paul Black, Tony
Conley, Jim Turpin, Fulvia Veronese and Opendra Sharma
from DAIDS, NIAID, NIH, was held on September 24,
2007 at Bethesda for the purpose of bringing together key
model developers and potential users. The meeting
included a discussion by a panel about the current status
of the models, future plans, as well as potential use of the
models for addressing critical issues in basic immune
response studies, pathogenesis, therapeutics, vaccines and
microbicides development. Speakers were asked to
address the following questions:
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Model advantages
What unique advantages does your model offer over the other
recently reported humanized mouse and rat models versus
SCID-hu and HuPBL-SCID, and existing non-human primate
models?
Possible studies
What types of studies does your model permit that were not pos-
sible previously? Can you expand on categories of studies, for
example. therapeutics, vaccines, PrEP, PEP, pathogenesis,
immunology studies, prevention, and microbicides.
Limitations
What are the limitations of your model? Be honest!
Cohort size
What size cohorts of mice can you routinely make? How many
reconstituted mice can you make per week/month? Are these
available to other investigators? If not, what are the limita-
tions? How consistent and reproducible are reconstitution and
infection in your system? Please provide percentages of success
for infection and numbers of mice that can be generated (week
or month) based on your experience.
Model availability
How widely is your system, available especially the strain of
mice used? Who supplies your mice? Is your mouse strain com-
mercially available? If it is commercially available and you do
not use it please explain why not.
Stem cells and fetal tissue
Please provide the following details about the stem cells/fetal
tissue used for the model: source and availability; amount
needed for your model; can they be pooled from multiple
donors; and must the cells/tissue be fresh or can they be frozen?
Model development
Please provide the details of the model development. We are
particularly interested in parameters such as titer of inoculating
virus, characteristics of the virus(s) used (strain, source), use of
cell-free and/or cell-associated virus, if a laboratory isolate or a
clinical isolate is used, and what clades, routes of inoculation,
and efficiency of infection (methods and ranges for the end-
point) have been used and measured.
Human cell distribution
What are the identity (including subsets R5/X4 expression),
functionality, and tissue distribution of subtypes of human
immune cells in blood and at mucosal sites? Please include
information on the female reproductive tract, rectum, lung, and
GALT in these models and variations from animal to animal.
How do these parameters compare to similar human sites? If
your model does not have a human thymic epithelium, how do
immature T cells get educated (positive and negative selec-
tion)?
Current scientific studies
Provide a brief overview of some of the scientific studies that
have been possible with your model so far. Unpublished data is
encouraged!
HLA restriction and antibody responses
Are there human HLA-restricted CD4 or CD8 responses? Are
there antigen-specific human antibody responses and how do
antibody titers compare with responses in humans?
Two broad approaches have been used to circumvent the
replication blocks in rodents to generate small animal
models for studying HIV infection. One broad approach
used transgenic techniques to generate mice or rats capa-
ble of supporting HIV replication either by introducing
transgenes encoding the human proteins critical for HIV
replication or an HIV provirus into the genome of
rodents. At the workshop, Drs. Littman, Keppler and
Goldstein discussed these approaches. A second increas-
ingly adopted approach utilizes chimeric human/mouse
models to circumvent the inability of mouse cells to sup-
port HIV replication by transplanting human hematopoi-
etic cells and/or human thymic tissues and/or fetal liver
into immunodeficient mice. A model initially described
by the McCune group designated either the SCID-hu
mouse [5] or the thy-liv SCID mouse was constructed by
surgically implanting fragments of human fetal thymus
and liver under the kidney capsule of a SCID mouse. Two
to three months after implantation, a thymus-like con-
joint human organ grows which supports long-term
multi-lineage hematopoiesis that leads to maturation of
human thymocytes [6]. If sufficient thymic tissue is
implanted, human T-cells are found in the peripheral
blood for over a year, but no mature B cells are generated
[7,8]. Injection of HIV-1 into the implant results in the
killing of human thymocytes and the severe depletion of
human CD4+ cells in the implant within a few weeks as
well as plasma viremia. A limitation of this model is that
no humoral or cellular responses to the HIV infection,
including primary immune responses, occur in these chi-
meric mice [6,9]. This model is also limited by its con-
struction using implanted tissues that are of fetal origin
whose response to infection may not necessarily reflect
the course of HV infection in patients where HIV predom-
inantly infects lymph nodes and the gut associated lym-
phoid tissues. In a presentation at the workshop Dr.
Stoddart discussed the current status and uses of this
model. The chimeric human/mouse approach has been
expanded by the recent description of new models that
take advantage of novel mouse strains, Rag2-/-γc
-/- mice
and NOD/SCID/IL2Rγnull mice, that are more immunode-
ficient than SCID mice and support engraftment and mat-
uration of human hematopoietic stem cells into human T
cells, B cells, monocytes and dendritic cells after injection
with human CD34+ hematopoietic stem cells [10-16].AIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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Drs. Akkina, Luban, Su, and Speck discussed their experi-
ences with models that use Rag2-/-γc
-/- mice and Dr. Shultz
has included his experience with a model that uses NOD/
SCID/IL2Rγnull  mice. Another chimeric human/mouse
model was discussed by Dr. Martinez that combines
human thymic implantation and transplantation with
human HSC by implanting NOD/SCID mice with fetal
liver and thymus and then transplanting them with syn-
geneic human CD34+ hematopoietic stem cells [17]. A
synopsis of these presentations and Tables summarizing
the techniques used to construct these models, the major
features of the different models and the specific experi-
ences of individual investigators using these models for
HIV-related studies are presented below.
Transgenic rodent models
Dr. Littman (Howard Hughes Research Institute, New
York University Medical Center) has been working on uti-
lizing transgenic approaches to overcome the replication
barriers that prevent HIV infection of murine T cells
(Table 1). These include the inability of HIV to enter
mouse cells, the subsequent inefficient support of Tat-
mediated trans-activation, the aberrant processing of HIV-
Gag protein and the defective virion budding in mouse
cells. To overcome the entry block, Dr. Littman used tran-
scriptional regulatory sequences from mouse and human
CD4 genes to construct transgenic mice expressing human
CD4 and CCR5 in mouse CD4+ T cells, myeloid cells,
dendritic cells and microglia. Using a Vpr-β-lactamase
assay, his group demonstrated that HIV could efficiently
enter into activated CD4+ T cells from these hCD4/CCR5
transgenic mice. After entry, he demonstrated that RT was
functional in primary mouse T cells as indicated by the
efficient generation of nuclear 2-LTR circles. The block
due to inefficient Tat-mediated trans-activation is related
to structural differences between mouse and human cyc-
lin T1 (hCyclin T1), a protein which is required for Tat
function and efficient HIV replication. A single amino
acid difference at position 261 in mouse cyclin T1 (mCy-
clin T1) compared to hCyclin T1 prevents mCyclin T1
from binding of HIV Tat. The Littman group constructed
mice transgenic for hCyclin T1 under the control of the
CD4 promoter and crossed them with hCD4/CCR5 mice.
Although expression of hCyclin T1 was associated with a
several-fold increase in the production of HIV by mouse
cells also expressing CD4 and CCR5, HIV RNA levels in
the infected hCycT1 mouse T cells were still 10-fold lower
than human cells. Efficient infection of mouse T cells
required continued activation of the TCR with anti-CD3/
CD28, particularly for the 12–20 hour period after infec-
tion. HIV production by mouse cells is also limited by a
processing defect in the conversion of the gag p55 precur-
sor to p24, leading to decreased production of p24 anti-
gen which is required for construction of the viral capsids.
Furthermore, the HIV produced by the mouse cells was
less infectious than HIV produced by human cells. Elec-
tron microscopy demonstrated the abnormal budding of
HIV in infected mouse T cells into the nuclear envelope
and not the cell membrane. Murine Apobec3 cannot
interact with HIV Vif, and hence can also inhibit HIV pro-
duction by mouse cells, but this has not yet been fully
assessed in murine T cells. This transgenic mouse model
therefore does not support sufficient levels of HIV replica-
tion for pathogenesis, drug or vaccine studies.
These transgenic mice were developed to also study the
pathogenesis of HIV-1 infection. Early in the course of
HIV infection, CCR5+CD4+ T cells are depleted from the
lamina propria in HIV-infected individuals which is not
reversed despite treatment with HAART. Critical questions
that need to be addressed are the mechanism for this
selective depletion of mucosal CD4 T cells, what interven-
tions can reverse this depletion, and the role of dendritic
cells and TH17 cells in this process. Development of a
mouse model infectible with HIV would greatly support
investigation of these critical questions. Future studies of
the Littman group will focus on identifying barriers to gag
processing in mouse cells, how to regenerate the CD4+ T
cell population in the mucosal associated lymphoid tis-
sues (MALT) after HIV infection and the role of dendritic
cells in HIV infection of MALT.
Dr. Goldstein discussed an alternative approach used in
his laboratory to construct mice that are transgenic for a
provirus encoding a full length primary R5-tropic isolate,
HIV-1JR-CSF, capable of producing HIV proteins and infec-
tious virus, JR-CSF mice (Table 1) [18]. To circumvent the
restricted trans-activating function of the Tat protein in
mice and to specifically target HIV replication to CD4-
expressing cells, Dr. Goldstein crossed the JR-CSF mice
with transgenic mice that carry a transgene of hu-CycT1
under the control of the CD4 promoter and express hu-
CycT1 in CD4 T cells, monocytes/macrophage dendritic
cells and microglia to yield JR-CSF/hu-CycT1 mice [19].
As a consequence of being able to support Tat-mediated
transactivation in CD4-expressing cells, HIV production is
markedly increased in the JR-CSF/hu-CycT1 mouse CD4 T
cells, monocytes and microglia. Stimulated JR-CSF/hu-
CycT1 mouse CD4 T cells produced between 1- to 10% of
the quantity of HIV produced by activated JR-CSF/hu-
cycT1 mouse monocytes, indicating that mouse T cells
have a specific block in post-HIV replication that is absent
in mouse monocytes. While the population of peripheral
CD4 T lymphocytes in the peripheral blood of JR-CSF
mice remained stable over time, the peripheral CD4 T
cells population in the JR-CSF/hu-cycT1 mice became
gradually depleted so that by one year of age the CD4 to
CD8 T cell ratio in the peripheral blood of the JR-CSF/hu-
cycT1 mice had reversed to less than one, similar to the
temporal course in HIV infected individuals that developAIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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Table 1: Transgenic Rodent Models
Dr. Goldstein Dr. Keppler Dr. Littman
Characteristics of Humanized 
Rodent Models
Strain Full-length LTR-regulated HIV 
provirus and CD-promoter 
regulated human cyclin T1 
expressed as transgenes in mice
Human CD4, CCR5 and cycin T 1 
expressed as transgenes in 
Sprague-Dawley rats
Human CD4, CCR5 and cycin T 1 
expressed as transgenes in mice
# mice/donor NA NA NA
Source of human cells NA NA NA
Method of isolation NA NA NA
Pre-transplant treatment-mice NA NA NA
Pre-transplant treatment-cells NA NA NA
Time frame from construction to 
experimental use
immediately Immediately immediately
Location of human hematopoiesis NA NA NA
Location of human Thymopoiesis NA NA NA
Reproducibility of engraftment (% 
mice engrafted)
NA NA NA
Identity of specific human 
leukocytes present
NA NA NA
Populated tissues HIV provirus and infectious HIV 
produced by CD4 lymphocytes, 
macrophages, DC and microglia in 
all organs analyzed
Human transgenes expressed in 
rat CD4 lymphocytes, 
macrophages and microglia in all 
tissues analyzed
Mouse CD4 T cells and monocyte 
lineages, including macrophages, 
dendritic cells, and microglia
Characteristics of HIV 
Infection of Humanized 
Rodent Models
HIV-specific immune response None Robust seroconversion, cellular 
responses not analyzed.
not examined
Tropism/clade of infecting HIV R5- HIV-JR-CSF R5 HIV-1 (YU-2 and V3 loop 
recombinant NL4-3) for CD4/
CCR5-tg; NL4-3 for CD4/CXCR4-
tg (unpublished)
R5 HIV strains (CCR5 Tg mice) 
and X4 strains (CXCR4 Tg mice)
Target cells infected All cells CD4 T-cells, macrophages CD4+ T cells, macrophages, 
microglia
Level of plasma HIV viremia 102~105 copies RNA/ml 2 × 102 RNA/ml (transient) not observed
Duration of the infection Life of the mouse Low level viremia up to 7 weeks, 
low levels of 2-LTR circles at 6 
months
not observed
Replication kinetics Inducible by cellular activation NA NA
In vivo generation of ART 
resistance
NA NA NA
Treatment of HIV Infection 
Using Humanized Rodent 
Models
Not examined due to lack of 
replication in vivo
ART to block transmission NA Pre-EP and post-EP for efavirenz, 
enfuvirtide
NA
Microbicide to block transmission NA NA NA
ART to control replication NA NA NA
Emergence of resistance to ART NA NA NA
Elimination of HIV reservoirs NA NA NA
HSC gene therapy to protect 
progeny cells
NA NA NA
CD4 T cell gene therapy to 
protect cells
NA NA NA
Immune-based Therapy of 
HIV Infection Using 
Humanized Rodent Models
Preventive HIV vaccines NA In progress (humoral immunity) NA
Treatment HIV vaccines NA NA NA
Adoptive Anti-HIV Ig therapy NA NA NA
Adoptive Anti-HIV CTL therapy NA NA NA
Immunoadjuvent therapy NA NA NAAIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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AIDS. In addition to being useful for studying the patho-
genesis of HIV-mediated depletion of CD4 T lymphocytes
in lymphoid tissues, these mice can also be used to inves-
tigate the in vivo effects of HIV infection on other organs,
including the brain. The Goldstein group demonstrated
that microglia and astrocytes from the JR-CSF/hu-cycT1
mice are more sensitive to in vivo activation by inflamma-
tory stimuli such as LPS than are microglia from JR-CSF
mice or wild-type littermates that is manifested by more
extensive phenotypic changes and increased production
of chemokines including of MCP-1. These mice provide a
useful model for investigating the direct and indirect long-
term effects of HIV-infection on cellular and organ func-
tion.
Dr. Keppler is pursuing the goal of humanizing rats to
generate an immunocompetent multi-transgenic rat
model of HIV-1 infection (Table 1). While cells from
native rodents do not or only inefficiently support distinct
steps of the HIV replication cycle, rats appear to be intrin-
sically more permissive than mice for supporting HIV rep-
lication. Of conceptual importance, the barriers to HIV
replication in rat cells identified thus far appear to result
from the inability of individual rat proteins to support
HIV-1 replication rather than from the action of species-
specific restriction factors. To circumvent these barriers,
the Keppler group has pursued a block-by-block approach
to humanize Sprague Dawley rats by the introduction of
human transgenes that encode proteins that are required
to overcome these barriers. Transgenic rats that express the
HIV receptor complex hCD4 and hCCR5 on CD4 T-cells,
macrophages and microglia (hCD4/hCCR5 rats) can be
infected systemically with HIV [20,21]. Following intrave-
nous challenge with HIV-1, lymphatic organs from hCD4/
hCCR5 rats contained HIV cDNAs and early viral proteins,
demonstrating successful in vivo infection. Furthermore,
hCD4/hCCR5 rats infected with HIVYU2 displayed low-
level plasma viremia (~150 copies/ml) for up to 7 weeks
post-challenge as well as episomal HIV cDNA species in
splenocytes and thymocytes 6 months post-infection. A
recent proof-of-principle study showed the suitability of
these double-transgenic animals for the rapid preclinical
evaluation of the inhibitory potency and of pharmacoki-
netic properties of antiviral drugs targeting HIV entry or
reverse transcription [22]. Prophylactic administration of
Sustiva (efavirenz) or Fuzeon (enfuvirtide, T20) markedly
inhibited the level of HIV infection measured several days
after in vivo challenge with HIV. Additional novel drugs,
including an integrase inhibitor, are currently being
tested. In contrast, administration of a semen-derived
fibril-forming peptide that has been shown by the Kirch-
hoff group to promote in vitro HIV infection increased the
splenic HIV cDNA load in hCD4/hCCR5 rats after in vivo
HIV challenge by 4.5 fold [23]. In their attempts to further
enhance the HIV susceptibility of transgenic rats, the lim-
ited support of HIV replication at the transcriptional level
that leads to reduced early HIV gene expression in rat T-
cells was largely surmounted by the transgenic expression
of a third human transgene, the Tat-interacting protein
hCyclin T1, a component of the P-TEFb transcription
complex [20]. T-cells from triple-transgenic rats produced
3-fold higher levels of HIV early gene products than rats
transgenic only for hCD4 and hCCR5. However, robust
replication is still precluded, most probably due to a dis-
proportional representation of Rev-dependent HIV RNAs
and viral proteins. The current work of the Keppler group
focuses on the identification of a relevant factor that may
overcome this third and possibly final barrier to HIV rep-
lication in primary target cells in rats. As a complementary
approach, the Keppler group is pursuing strategies to
adapt HIV to replicate in primary T-cells from transgenic
rats.
Chimeric human/mouse models
The generation of humanized mice for HIV research has
benefited from a progression of genetic modifications
made possible by the occurrence of spontaneous immu-
nological mutations, the targeting of genes required for
the development of innate and adaptive immunity, and
the availability of inbred mouse strains exhibiting
depressed innate immunity. The first widely used model
for human hematolymphoid engraftment and subse-
Investigation of HIV 
Pathogenesis
Not yet examined due to lack of 
replication
Contribution of HIV genes to 
pathogenesis
yes NA NA
HIV-mediated CD4-depletion-
lymphoid
yes NA NA
HIV-mediated CD4-depletion-
mucosal
yes NA NA
Effects of co-factors on replication yes CD4, CCR5, CXCR4, CyclinT1 CD4, CCR5, CXCR4, Cyclin T1, 
DC-SIGN
Effects of co-infection e.g. mTb on 
replication
yes NA NA
End organ dysfunction yes NA NA
NA = not applicable
Table 1: Transgenic Rodent Models (Continued)AIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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quent HIV infection was the CB17-Prkdcscid (abbreviated
as  scid)  mouse. CB17-scid  mice supported engraftment
with human (HSC), peripheral blood mononuclear cells
(PBMC), and human fetal tissues. However, levels of
engraftment were limited by many factors including host
natural killer (NK) cell activity, spontaneous generation of
mouse lymphocytes (leakiness), and the occurrence of
spontaneous thymic lymphomas [24]. The subsequent
development of the NOD-scid  mouse stock exhibiting
depressed NK cell activity resulted in heightened support
of human hematolymphoid engraftment [24,25].
Humanized mice were incrementally improved over the
next decade by the targeting of genes at a number of loci
including the recombination activating genes 1 and 2
(Rag1  and  Rag2)  and the beta 2 microglobulin (B2m)
locus [26]. Mutations at the Rag-1 and Rag2 loci prevent
development of mature mouse lymphoid cells but do not
reduce NK cell activity. The B2m mutation prevents NK
cell development. Although NOD-scid B2mnull mice lack
NK cell activity, a shortened lifespan due to early occur-
rence of thymic lymphomas and other pathologic changes
limited the use of this model in HIV research [27].
A major advance in development of humanized mice was
made possible by the targeting of the gene encoding the
interleukin-2 receptor common gamma chain (Ilrg),
abbreviated as IL2Rγ. The IL2Rγ chain is indispensable for
IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 high affinity binding
and signaling [28]. The IL2Rγ mutation prevents NK cell
development and causes other defects in innate immunity
as well as depressed adaptive immunity. In humans, IL2Rγ
deficiency causes X-linked SCID [29]. Four different
groups independently targeted the mouse IL2Rγ gene [30-
33]. Genetic crosses of IL2Rγ null mice with scid, Rag1null
and Rag2null mice on a several different mouse strain back-
grounds resulted in a number of new immunodeficient
models that support engraftment with human HSC,
PBMC, and fetal tissues [26].
NOD/SCID/IL2Rγnull mouse model
Dr. Shultz and his colleagues, Drs. Dale Greiner and
Fumihiko Ishikawa generated mice chimeric for the
human hematopoietic system using one of the most
widely available of the IL2Rγ deficient mouse stocks, the
NOD-scid Il2rgtm1wjl (NOD-scid IL2Rγnull) model (Table 2).
These mice lack mature lymphocytes and NK cells, survive
beyond 16 months of age, and do not develop lympho-
mas [34]. The Shultz group demonstrated that newborn
[12] and adult [34] NOD-scid IL2Rγnull mice support high
levels of engraftment with human umbilical cord blood
(UCB) HSC and mobilized HSC. The human HSC
engrafted mice develop mature human lymphoid and
myeloid cells and mount a humoral immune response to
thymic-dependent antigens [11,12]. Engraftment of
NOD-scid IL2Rγnull mice with either human committed
lymphoid or myeloid progenitor cells isolated from
human UCB results in development of both human con-
ventional and plasmacytoid dendritic cells [35]. Adult
NOD-scid IL2Rγnull mice also support heightened engraft-
ment with human PBMC following intravenous, intra-
peritoneal, or intrasplenic injection [36]. Current ongoing
genetic modifications of the NOD-scid IL2Rγnull model in
Dr. Shultz's lab include further reductions of innate
immunity as well as transgenic expression of human HLA
molecules, cytokines, and other components needed to
optimize human hematolympoid engraftment and func-
tion.
RAG2-/-γc
-/- mouse models
Dr. Akkina generated mouse-human chimeric mice using
fresh CD34+ HSC isolated from human fetal liver cul-
tured with cytokines for 1 day at a low density and
injected hepatically (250,000 CD34+ cells/mouse) into
RAG2-/-γ
c
-/- Balb/c mice obtained from Dr. Irving Weiss-
man (RAG-KO mice) (Table 3) [10]. Within the first 3
days of life, neonatal RAG-KO mice are sublethally irradi-
ated and injected intrahepatically with CD34+ human
hematopoietic stem cells to yield RAG-hu mice. After 8–
12 weeks, the peripheral blood of the RAG-hu mice is
populated with human T cells (CD4+, CD8+), B cells,
dendritic cells, and macrophages. The fraction of CD45+
leukocytes detected in the peripheral blood of the RAG-hu
mice of human origin was between is 5–80% and the
Akkina group now routinely generate RAG-hu mice where
the fraction of human peripheral blood lymphocytes is
greater than 30% and human CD45+ leukocytes populate
the mouse primary and secondary lymphoid organs. In
addition, human T cells, macrophages and dendritic cells
were detected in the vaginal, rectal and intestinal mucosa
[37]. In the RAG-hu mice, human hematopoiesis contin-
ues for more than 1 year as evidenced by the maintenance
of a stable population averaging 20–50% of human C45+
leukocytes in the peripheral blood.
The RAG-hu mice are infectible with a variety of X4 and
R5 isolates, have plasma viremia and circulating human
PBMC containing HIV that is detectible by PCR [10]. The
level of viremia in the plasma ranged up to 165,000–
12,200,000 copies/ml, but may rise and fall over time.
HIV infection is detected in lymphoid tissues and CD4
depletion occurs after HIV infection, but the extent of
CD4 depletion can vary widely during infection. The
infection has persisted for a long time, with HIV detected
in the RAG-hu bone marrow almost 1 year after inocula-
tion. Mucosal HIV transmission occurred in RAG-hu mice
as evidenced by the development of plasma viremia
within 1 week after the mice were infected vaginally and
rectally with an R5 HIV isolate without any prior hormone
treatment or introduction of mucosal abrasion. This pri-
mary transmission was associated with the disseminationAIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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Table 2: SCID Mouse and NOD/SCID mouse-based chimeric human models
Dr. Stoddart Dr. Shultz Dr. Garcia-Martinez
Characteristics of Humanized 
Rodent Models
Strain C.B-17 scid/scid (Taconic) NOD-SCID IL2r gamma -/- NOD/SCID
# mice/donor 50–60 mice/donor CD34+ cell isolation yields 1 × 106 
cells/donor sufficient for engrafting 
20- to 25 mice
25
Source of human cells Human fetal liver and thymus (20–
24 g.w.)
Umbilical cord blood; mobilized 
hematopoeitic stem cells
Fetal liver/thymus
Method of isolation not applicable Magnetic bead enrichment Magnetic beads
Pre-transplant treatment-mice None 100 cGy for newborns; 325 cGy 
for adults; Intravenous injection
325 rads
Pre-transplant treatment-cells None None None
Time frame from construction to 
experimental use
18 weeks 12 weeks 8–12 weeks
Location of human hematopoiesis Thy/Liv organ Bone marrow Bone marrow
Location of human Thymopoiesis Thy/Liv organ Mouse thymus Human thymic tissue
Reproducibility of engraftment (% 
mice engrafted)
90–100% with >80% CD4+CD8+ >90% of newborn and adult mice 
are engrafted in the bone marrow, 
spleen and thymus
>95%
Identity of specific human 
leukocytes present
Immature and mature T cells, B 
cells, macrophages, plasmacytoid 
DCs
B cells, T cells, conventional and 
plasmacytoid DCs, macrophages, 
monocytes, RBCs, platelets
T and B cells, DCs, monocytes/
macrophages, NK, NKT and Tregs
Populated tissues Human Thy/Liv organ Bone marrow, thymus, spleen, 
lymph nodes, intestine, blood
GALT, Female and male 
reproductive tract, lung, bone 
marrow, lymph nodes, thymus, 
spleen, liver, peripheral blood.
Characteristics of HIV 
Infection of Humanized 
Rodent Models
HIV-specific immune response None reported Work in progress Yes, human IgG
Tropism/clade of infecting HIV X4, R5, dual/mixed; clade B Not tested R5 and X4
Target cells infected Intrathymic progenitors (CD3-
CD4+CD8-), immature and 
mature thymocytes, macrophages
Not tested CD4 T cells, monocytes/
macrophages, DC
Level of plasma HIV viremia None to highly variable Not tested Variable depending on stain of 
virus and tropism
Duration of the infection 5 weeks until severe depletion for 
X4 and dual/mixed; >6 months for 
R5
Not tested Variable depending on stain of 
virus and tropism
Replication kinetics Peaks at 3 weeks post infection 
(wpi) (X4 and dual/mixed), 6 wpi 
(R5)
Not tested Isolate dependent
In vivo generation of ART 
resistance
Not observed for NL4-3 and 3TC 
(no RT M184V)
Not tested Not done
Treatment of HIV Infection 
Using Humanized Rodent 
Models
ART to block transmission Not feasible Yes Not tested
Microbicide to block transmission Not feasible Yes Not tested
ART to control replication Yes, 4 classes of licensed ARVs so 
far.
Yes Not tested
Emergence of resistance to ART Not observed for NL4-3 and 3TC 
(no RT M184V)
Not done Not tested
Elimination of HIV reservoirs Not performed Not done Not tested
HSC gene therapy to protect 
progeny cells
Not performed yes Not tested
CD4 T cell gene therapy to 
protect cells
Not performed Not done Not tested
Immune-based Therapy of 
HIV Infection Using 
Humanized Rodent Models
Preventive HIV vaccines Not feasible Yes Not testedAIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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of infection to mouse lymph nodes, intestines and spleen.
X4 HIV isolate was also found to be capable of mucosal
transmission via both vaginal and rectal routes although
the efficiency of infection was lower than R5 virus. Mucos-
ally infected RAG-hu mice displayed CD4 T cell depletion,
but depletion occurred later and was not as dramatic as
seen in mice after intraperitoneal infection. Advantages of
the RAG-hu model for studying HIV infection include its
capacity to support chronic productive HIV infection for
over 1 year, to display CD4 depletion and to being suscep-
tible to infection by either vaginal or rectal routes.
HIV infection may undermine the human immune
response of RAG-hu mice. Studies using the RAG-hu
mouse system by the Akkina group to model Dengue
fever, for which there is currently no ideal animal model
available to study viral pathogenesis and to test vaccines,
may be more informative of the capacity of RAG-hu mice
to generate primary human immune responses [38].
There are 4 serotypes of Dengue virus and re-infection of
individuals with a second serotype virus causes worse dis-
ease than infection with the primary virus due to anti-
body-dependent enhancement. After challenges of RAG-
hu mice with Dengue virus the mice become infected and
develop Dengue-specific antibody. Viremia (106 particles/
mL) lasts up to 2 weeks and Dengue viral replication is
detected in the mouse spleens. Dengue-specific IgM and
IgG responses are first detected at 2 weeks and at 6 weeks
after infection, respectively. Dengue virus neutralization
was detected in the sera of some mice at a titer of up to
1,000 by using a FACS-based assay. Of interest was the
observation that the immune response to Dengue was
much more robust than the immune response to HIV after
infection. This may reflect HIV-associated compromise of
the human immune system in the RAG-hu mice.
Future studies by the Akkina group using this model will
include evaluating the long-term effects of microbicides,
studying viruses that infect the hematolymphoid system,
evaluating gene therapy strategies using vectors carrying
anti-HIV genes and drug-selection makers, investigation
of the mechanism of antibody-dependent enhancement
during Dengue infection and the testing of Dengue vac-
cines.
Dr. Luban reported on the system developed by Markus
Manz at his Institute, of injecting human CD34+ HSC int-
rahepatically into newborn Balb/c RAG2-/-γc-/- mice (Table
3) [15]. These mice were obtained from Dr. Weissman,
who originally got them form Dr. Mamoru Ito in Japan.
Strain-specific factors contributed to the degree of recon-
stitution. Mice carrying the same RAG2 and γ c deletions
on the C57BL/6 background did not become reconsti-
tuted with human leukocytes. In contrast, the lymphoid
tissues of the Balb/c RAG2-/-γc-/- mice display reconstitu-
tion with human B cells and T cells and population of the
thymus with human T cells. No significant population of
human leukocytes was detected in the mouse mucosa or
brain. After intra-peritoneal injection of either the R5 or
X4 strains of HIV, YU2 and NL4-3, respectively, the mice
developed systemic infection with sustained plasma
viremia of up to 106 HIV RNA copies/ml [39].
The γc
-/- mice used in these studies have a partial deletion
of the common gamma chain receptor gene with expres-
sion of a truncated common gamma chain receptor that
binds the appropriate cytokine, but lacks the intracellular
signaling region. It is unclear if this truncated receptor has
any functional activity, but mice having complete dele-
tion of the common gamma chain receptor are also avail-
able. The litter size of the Balb/c RAG2-/-γc-/- mice ranges
from 3 to 11 mice, with an average of about 6 mice. Their
group obtains sufficient human CD34+ HSC from each
cord blood donor to inject an average of 4–6 mice. After
reconstitution of the mice, analysis of whole blood after
RBC lysis, demonstrated that the peripheral blood of 90%
Treatment HIV vaccines Not feasible Not done Not tested
Adoptive Anti-HIV Ig therapy Feasible, but not performed Not done Not tested
Adoptive Anti-HIV CTL therapy Feasible, but not performed Not done Not tested
Immunoadjuvent therapy Not feasible Not done Not tested
Investigation of HIV 
Pathogenesis
Contribution of HIV genes to 
pathogenesis
Nef, Env (coreceptor usage), 
protease
Yes Not tested
HIV-mediated CD4-depletion-
lymphoid
Thy/Liv organ Yes Not tested
HIV-mediated CD4-depletion-
mucosal
Not applicable Yes Not tested
Effects of co-factors on replication Not determined Yes Not tested
Effects of co-infection e.g. mTb on 
replication
Not determined Yes Not tested
End organ dysfunction Thy/Liv organ undergoes severe 
thymocyte depletion
Yes Not tested
Table 2: SCID Mouse and NOD/SCID mouse-based chimeric human models (Continued)AIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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Table 3: Rag2-/-γc-/- Mouse-based Human Chimeric Model
Dr. Akkina Drs. Speck and Luban Dr. Su
Characteristics of Humanized 
Rodent Models
Strain Balb/c-Rag2-/-γ c-/- Balb/c-Rag2-/-γ c-/- Balb/c-Rag2-/-γ c-/-
# mice/donor 40/donor CD34+ cell isolation yields 1–2 × 
106 cells/donor sufficient for 5–10 
mice (1 litter)
20–50/donor
Source of human cells Fetal liver Cord blood Fetal liver
Method of isolation Magnetic bead enrichment for 
CD34+ cells
Magnetic bead enrichment for 
CD34+ cells
CD34+ MACS kit
Pre-transplant treatment-mice Irradiation 350 rads; intrahepatic 
injection into newborns
Irradiation 200 rads given twice 4 
h apart; intrahepatic injection into 
newborns
Irradiation 400 rad; intrahepatic 
injection into newborns
Pre-transplant treatment-cells SCF, IL-3, IL-6 None None or retroviral transduction
Time frame from construction to 
experimental use
12 weeks 12–16 weeks >12 weeks
Location of human hematopoiesis Bone marrow Not investigated BM, Spleen, LN
Location of human Thymopoiesis Mouse thymus Not investigated Mouse thymus
Reproducibility of engraftment (% 
mice engrafted)
>95% More than 90% of mice show 
human cells in periphery; about 
50% of mice have levels >10% 
huCD45+ cells
>95% with >20% human CD45+ 
cells in blood
Identity of specific human 
leukocytes present
T and B cells, DCs, monocytes/
macrophages and some 
granulocytes
B and T cells, monocytes, DCs All human leukocytes
Populated tissues Bone marrow, lymph nodes, 
thymus, spleen, liver, intestines, 
lungs
Thymus, spleen, blood, MLN, BM, 
liver; to some extent: gut
BM/thymus/spleen/LN (no 
significant Peyer's patches found)
Characteristics of HIV 
Infection of Humanized 
Rodent Models
HIV-specific immune response Not detected Some minor B cell response (1/25 
animals tested); no T cell response 
detected
Low gag-specific responses/no IgG 
detected
Tropism/clade of infecting HIV R5, X4, dual-tropic YU-2 and NL4-3 R5-X4-dual or R5/clade B
Target cells infected CD4 T cells CD3+ cells and only occasionally 
non T cells such as CD68+ 
macrophages
CD4 T and DC
Level of plasma HIV viremia ~107 copies RNA/ml Up to 2 × 106 copies/ml 105-106 copies/ml
Duration of the infection at least 14 months Up to 190 days; longest period 
followed
>22 weeks
Replication kinetics Peak viremia at about 6 weeks 
followed by maintenance of 
viremia
HIV RNA levels peak 2–6 wpi, 
thereafter viremia mostly stabilizes 
at lower levels.
HIV RNA levels peaks at 2–3 (dual 
tropic) or 4–6 wpi (R5-tropic)
In vivo generation of ART 
resistance
Not done Not tested Not known
Treatment of HIV Infection 
Using Humanized Rodent 
Models
ART to block transmission Not done Not done Not done
Microbicide to block transmission Not done Not done Not done
ART to control replication Not done Not done Yes.
Emergence of resistance to ART Not done Not done Not done
Elimination of HIV reservoirs Not done Not done Not done
HSC gene therapy to protect 
progeny cells
yes Not done Not done
CD4 T cell gene therapy to 
protect cells
Not done Not done Not done
Immune-based Therapy of 
HIV Infection Using 
Humanized Rodent Models
Not done
Preventive HIV vaccines Not done Not done Not done
Treatment HIV vaccines Not done Not done Not doneAIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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of the mice was populated with >5–10% human CD45+
cells. An aliquot of cord blood yields an average of 5 × 105
CD34+ cells, with a range of 2 × 105 – 2 × 106 cells. Cord
blood from separate donors can be pooled and one donor
provides sufficient human CD34+ cells to reconstitute
one litter of mice. The CD34+ cells can be frozen and, in
fact, the majority of their mice are reconstituted with fro-
zen cells.
Advantages of this model are that it uses no human fetal
tissues, requires no surgery, and displays no global activa-
tion of the human leukocytes populating the mouse lym-
phoid tissue. The mice are hardy, breed well and develop
no tumors in the thymus. These mice can be used to eval-
uate therapeutics, but their use for this purpose is limited
by the modest throughput. They can be used to study HIV
pathogenesis including which isolates infect brain and
other cell types, mechanisms of cell to cell spread, restric-
tion factor biology, and potentially in vivo imaging. They
also can be used to study the impact of viral genetic and
host genetic factors on HIV replication. This relatively fac-
ile reconsitution model may thus be an ideal system in
which to test antiviral gene therapy.
The human T cells are likely to mature in the mouse thy-
mus and interact with human dendritic cells that are
present in the mouse thymic epithelial tissues. Positive
selection is indicated by the presence of mature human T
cells in the periphery and negative selection is indicated
by the absence of graft vs. host disease [40].
After infection with HIV, low liters of HIV-specific anti-
body are detected in only 1 in 25 mice [39]. To use these
mice as a model to study vaccines needs improvement.
The low number of CD34+ HSC that can be isolated from
the cord blood limits the number of mice that could be
generated from isogenic CD34+ cells. Over several
months, the levels of human CD45+ cell declined, and
human CD45+ leukocytes were not detected in the
mucosa or lungs of the mice. The capacity of human leu-
kocytes to mature, differentiate and localize to the appro-
priate lymphoid tissue may be limited by the inability of
some mouse molecules to exert their functional activity
on human cells. The current mouse model permits intro-
duction of gene therapy vectors into human HSC, prior to
injection into the mice, including genes that could protect
mature human CD4 T cells from HIV infection. For this
purpose the Luban group is developing lentiviral vectors.
To circumvent the limited availability human HSC
derived from cord blood, Dr. Luban is attempting to gen-
erate human HSC from human ES cells.
Dr. Su uses the same Balb/c RAG2-/-γc-/- mouse (DKO
mouse) but circumvents the limitation of the low number
of CD34+ HSC obtainable from cord blood by using
human fetal liver as a source of human HSC (Table 3).
After intrahepatic injection of neonatal DKO mice with
human CD34+ cells (5 × 105 cells/mouse), the periphery
of the mice (hu-DKO mice) become populated with
human T cells, B cells and dendritic cells, including mDc
and pDC. The human leukocytes populate the mouse
spleen to about 1/3 the size of the normal mouse spleen
and the mouse thymus to about 20% of the size of the
normal mouse thymus. The human T cells undergo posi-
tive and negative selection during maturation as indicated
by the observation that the human cell-tropic EBV infec-
tion leads to effective anti-EBV T cell responses and circu-
lating human T cells (or splenocytes) do not generate a
mixed lymphocyte reaction (MLR) against human leuko-
cytes from another hu-DKO mouse transplanted with
human CD34+ HSC from the same donor but do generate
an MLR against human leukocytes isolated from a hu-
DKO mouse transplanted with CD34+ HSC from a differ-
ent donor. Although mesenteric nodes draining the intes-
tines of the hu-DKO mice contained human T cells and B
cells, they did not detect either Peyer's patches or signifi-
cant numbers of human CD45+ leukocytes in the lamina
propria of the gut. Immunization of the mice with an HBV
vaccine generated germinal centers in the mouse lymph
nodes. Although the mouse B cells do not express IgG,
Adoptive Anti-HIV Ig therapy Not done Not done Not done
Adoptive Anti-HIV CTL therapy Not done Not done Not done
Immunoadjuvent therapy Not done Not done Not done
Investigation of HIV 
Pathogenesis
Contribution of HIV genes to 
pathogenesis
yes Not done Env/Nef
HIV-mediated CD4-depletion-
lymphoid
yes yes Yes
HIV-mediated CD4-depletion-
mucosal
Not done Not done mesenteric LN, yes
Effects of co-factors on replication Not done Not done Not done
Effects of co-infection e.g. mTb on 
replication
Not done Not done Not done
End organ dysfunction Not done Not done Not done
Table 3: Rag2-/-γc-/- Mouse-based Human Chimeric Model (Continued)AIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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they can be driven in vitro to produce IgG if incubated
with T cells stimulated with anti-CD3 and anti-CD28. The
population of human T cells is not increased phenotypi-
cally in number by implantation of human thymic tissues
from the same donor, but the implanted mice subse-
quently developed rashes and became sick.
The hu-DKO mice were challenged by the Su group with
HIV through several routes. After intravenous infection
with the HIV isolate R3A, 100% of the mice become
infected. If the mice are challenged with cell-free HIV by
intrarectal inoculation, none of the mice became infected.
Intrarectal challenge with HIV-infected cells caused tran-
sient infection that was cleared by 3 weeks after inocula-
tion. When intrarectal inoculation with HIV-infected cells
was accompanied with mucosal injury, sustained HIV
infection occurred that was associated with depletion of
the peripheral human CD4 T cells. During the course of
infection, the level of plasma virus fluctuated and corre-
lated inversely with the number of human CD4 T cells in
the peripheral blood. The hu-DKO mice were used to
examine the role of HIV-induced immune activation in
mediating CD4 depletion. The Su group examined the
role of CD4 Treg cells in HIV infection using the hu-DKO
mice. HIV infects and replicates efficiently in CD4 Treg
cells. In the hu-DKO mice, about 3–5% of circulating CD4
T cells were CD25+ FoxP3+, the phenotype of CD4 Treg
cells. These CD4 Treg cells are functional, as evidenced by
their capacity to suppress T cell proliferation in an in vitro
assay. In hu-DKO mice, the R3A isolate of HIV infects and
rapidly depletes CD4 Treg cells. HIV-mediated depletion
of Treg with loss of their inhibitory regulatory activity may
contribute to HIV-mediated hyperimmune activation.
Dr. Speck presented his group's experience using hu-DKO
mice generated from Balb/c RAG2-/-γc-/- mice (DKO mice)
injected with human CD34+ HSC isolated from cord
blood either fresh or frozen and stored at -80°C (Table 3).
Close to 100% of the lymphocytes present in the lymph
node and thymus of the time were human. There was also
a large quantity of human dendritic cells in the liver. After
inoculation with HIV strains YU2 or NL4-3, the mice
developed sustained high levels of viremia, and displayed
CD4 depletion that was more extensive after infection
with NL4-3 than with YU2 [39]. In the thymus, extensive
infection with NL4-3 was detected, but almost no infec-
tion with YU2 was observed. About 1 in 25 mice gener-
ated HIV-specific antibodies. While construction of the
hu-DKO mice did not require the use of fetal tissue and
the hu-DKO mice developed sustained and disseminated
HIV infection, the infected hu-DKO mice generated
almost no HIV-specific immune responses. The mice dis-
played variable rates of engraftment and the function of
the engrafted leukocytes may vary depending on unique
genetic factors associated with the specific donor of the
CD34+ HSC. Use of these mice requires a BSL2/3 facility
and access to cord blood. Dr. Speck's group can generate
about 50 mice/month. Engraftment depends on the qual-
ity of the mice and for optimal engraftment new breeding
pairs are used every 3–4 months. Engraftment with
human leukocytes decreases over time and the percentage
of circulating human T cells needs to be above 1% to get
successful infection after intraperitoneal injection. How-
ever, the level of engraftment with human CD45+ leuko-
cytes does not predict the level of HIV replication after
infection.
Despite the generation of Ag-specific immune response to
model antigens, the hu-DKO mice displayed no or very
weak adaptive immune responses to HIV. They also did
not display hypergammaglobinemia, a hallmark of early
HIV infection. Only scattered human CD45+ leukocytes
were detected in the gut mucosa. After treatment of the
mice with progesterone, the mice exhibited thinning of
the vaginal epithelia and could be infected by the vaginal
route with HIV-infected PBMC but not with cell-free virus.
No human T cells were detected in the lamina propria and
human CD45+ leukocytes detected in the perianal tissues
were likely to be human macrophages.
NOD/SCID-based mouse models
Dr. Victor Garcia presented his results using a different
model, BLT mice (Table 2) [17,41] where human fetal
liver and thymus are divided into pieces that are surgically
implanted under the kidney capsule of NOD/SCID mice;
one fraction of the liver is used for isolation of CD34+
HSC that are frozen and three weeks after surgery, the
mice are sublethally irritated and intravenously injected
with the freshly thawed syngeneic CD34 HSC (0.25–2.5 ×
106 cells/mouse). One-to-two months after injection, 20–
50% of the circulating leukocytes in the peripheral blood
of the mice are human, and include human T cells, B cells,
monocytes and dendritic cells. The human T cells in the
peripheral blood express a broad range of Vβ TCRs. Func-
tional activity of the human DC was indicated by the
selective expansion of the human Vβ 2+ T cell population
after administration of TSST-1 with subsequent produc-
tion of TNF-γ, IFN-γ, IL-10, IL-6, IL-2, and IL-8 after 18
hours. After infection with EBV, the mice show an expan-
sion of the CD45RA-CD27+ memory T cells and the emer-
gence of human T cells that could generate IFN-γ
ELISPOTs in an MHC-restricted manner to autologous
EBV-infected lymphoblastoid cells. Functional activity of
the human lymphocytes was indicated by the observation
that in contrast to EBV-infected NOD/SCID mice, EBV-
infected BLT mice did not develop EBV-induced tumors.
The intestine and rectum of the BLT mice were populated
with human CD4+ T cells. No human cells were detected
in the brains of the BLT mice. The small intestines of the
mice were populated with human intraepithelial lym-AIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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phocytes (IEL) expressing CD8 α and β chains and lamina
propria lymphocytes (LPL) that only expressed the CD8
alpha chain. The number of human CD4+ T cells exceeded
the human CD8+ T cells in the small intestine but not in
the large intestine. The human CD4+ T cells expressed low
levels of CXCR4 and higher levels of CCR5. After mice
were challenged with the LAI strain of HIV, they became
infected as indicated by the presence of p24 antigen in the
plasma. Three of four infected mice had human antibod-
ies to gp120, p66 and p24 detected by Western blot. The
target cells for HIV infection were CD3+ CD4+ T cells and
after HIV infection there was almost complete depletion
of CD4+ T cells in the mesenteric lymph node and CD4+
and CD8+ T cells in the small intestine lamina propria.
Intrarectal infection with the JR-CSF stain resulted in sys-
temic HIV infection of the mice, but the CD4+ T cell
depletion was not as dramatic as that observed after intra-
venous infection. Systemic HIV infection could also be
introduced by intravaginal installation of both X4 and R5
isolates of HIV. This permitted the Garcia group to use
these mice to test the anti-HIV activity of microbicides.
They demonstrated that pre-exposure prophylaxis with a
proprietary microbicide completely protected the mice (n
= 5 mice) from systemic HIV infection after intravaginal
inoculation with HIV-1.
SCID Mouse-based mouse models
Dr. Stoddart presented her experience using the SCID-hu
Thy/Liv- mouse model (Table 2) [42]. This model, first
described by Dr. McCune, consists of SCID mice
implanted with syngeneic pieces of human fetal liver tis-
sues by surgical placement under their kidney capsules
[5]. A single donor provides sufficient tissue to implant
50–60 mice. The mice are implanted at about 8 weeks of
age, and by 18 weeks the implant grows into a tissue that
resembles human fetal thymus with sufficient volume to
infect by direct injection with HIV-1. This approach per-
mits the generation of about 1,200 mice/year. After direct
injection of HIV-1 into the implant, the thymic tissue
becomes infected with HIV, but the infection does not dis-
seminate outside the implant. After injection of the
thymic implant with the HIV-1 X4-tropic strain NL4-3, the
mice do not develop reproducible plasma viremia, and
implant viral loads peaks about 3 weeks after inoculation.
Dr. Stoddart demonstrated that the dose response and
antiviral activities of licensed ART in the SCID-hu model
was comparable to that observed during treatment of HIV-
infected individuals. A major advantage of the SCID-hu
model is that large cohorts of mice can be constructed
from the same donor removing a potential confounding
variable in comparative drug studies of the differential
response of tissues from different donors. This also per-
mits the production of mice at a low cost per mouse. The
SCID-hu mice can be infected with wild type or mutant
isolates of HIV-1 for the evaluation of anti-HIV therapy
against wild-type or drug-resistant mutants or investiga-
tion of the impact of mutations in HIV genes on in vivo
replicative capacity. Use of the SCID-hu Thy/Liv model is
limited by the requirement for fetal tissue, the need for
surgical construction of each mouse, the lack of immune
responses generated by the human T cells, and the limita-
tion of HIV infection to the human thymic implant.
Perspective and Recommendations
Dr. KewalRamani summarized the advantages and disad-
vantages of studying HIV infection using rodent-based
models compared to macaque-based models. Advantages
of the human chimeric mouse models are that they are
populated with human lymphoid and myeloid cells,
infectible with a broad range of HIV isolates, amenable to
genetic manipulation of the mouse recipient, able to reca-
pitulate variation among donor recipients and are rela-
tively inexpensive. Disadvantages of the human chimeric
models are their inability to generate a robust HIV-specific
immune response which precludes their use for testing
HIV vaccines, their requirement for human HSC and the
lack of regional centers. Dr. Lifson discussed the selective
infection of macaques with SIV and not HIV. Although the
pathogenic behavior of various strains of SIV isolates
closely resembles that of HIV including the induction of
CD4 depletion, development of CNS disease and persist-
ence of HIV in anatomical reservoirs during ART, experi-
mental results using SIV-infected macaques may not
correlate with the pathogenesis of HIV infection in
humans. While experiments using SIV-infected macaques
are expensive, the presence of regional primate centers
provides investigators with access to this primate model.
A panel of investigators discussed the following Questions
during Panel discussion:
What are the hindrances to widespread use of the models for
pathogenesis studies?
What is needed to determine the feasibility of the models for
vaccine and therapeutic testing, including testing of microbi-
cides?
What can be done to overcome some of the current blocks for
the models to support quality assays? Some of these include
CD34 cell suppliers, mice, how cells are treated, virus, others.
What can the NIH do to facilitate solutions to the above ques-
tions?
A limiting factor discussed by panel members was the var-
iable availability of these newer immunodeficient mice to
investigators. This could be circumvented by having
NIAID set up a centralized repository in an existing ani-
mal facility to permit establishing and replenishingAIDS Research and Therapy 2008, 5:3 http://www.aidsrestherapy.com/content/5/1/3
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mouse colonies for investigators. Another bottleneck is
the availability of human HSC. Three sources of human
HSC are available. The first is mobilized CD34+ HSC
obtained from GM-CSF-stimulated individuals, a modal-
ity used to obtain HSC autologous bone marrow for trans-
plant, particularly in individuals with leukemia. However,
Dr. Su stated that in his lab, mobilized human HSC did
not effectively engraft the DKO mice with human hemat-
opoietic cells. The second source of human HSC is cord
blood. While the number of HSC obtained from a cord
blood donor is only sufficient for reconstituting 4- to 6
mice, cord blood is readily available and an NIH-spon-
sored repository could be set up that provide cord blood
HSC to investigators. Furthermore, pooled CD34+ HSC
from several cord blood donors could be used for some
experiments requiring larger numbers of mice. The third
human HSC source is human fetal liver, which provides
sufficient numbers of CD34+ HSC to populate large quan-
tities of mice. However, because the source of this tissue is
from fetal abortuses, access to this tissue is restricted and
subject to additional review by oversight committees.
The panel highlighted several areas that should be the
subject of future scientific investigation to advance these
model systems, particularly identification of factors that
would increase the development of functional human
immune response in these mice. Although population of
the hu-DKO mouse thymus with human double and sin-
gle positive T cells was suggestive of it being the location
of human thymopoiesis, double positive T cells were also
detected in lymph nodes. Therefore, further dissection of
the mechanism of human T cell maturation in this system
could provide new methods to increase the qualitative
function of T cells that mature in the human mouse chi-
meric model. A critical technical issue was raised regard-
ing the importance of standardizing metrics for measuring
the population of human leukocytes in the peripheral
blood to permit the repopulation results of different
groups to be compared. To compensate for variation in
gating for live cells or lymphocytes, one approach would
be to report the ungated percentage of human CD45 cells
after lysis of whole blood while another approach would
be to report the population as the absolute number of
human leukocytes/ml of blood. Another area to investi-
gate is the mechanism of localization of mouse lymphoid
and myeloid cells to the mouse mucosal tissue. While Dr.
Akkina reported that the gut mucosal tissue of hu-DKO
mice constructed by his group were populated with
human leukocytes, relatively more extensive human leu-
kocyte engraftment in the mucosal tissue has been docu-
mented for the humanized BLT mouse model [17,41].
Delineation of the basis for the differential capacity of
human leukocytes to populate the mucosal associated
lymphoid tissues of mice may provide insights into the
mechanism for lymphocyte homing to the gut and other
mucosal areas. For example, is it a consequence of the dif-
ferent location of maturation of the human leukocytes in
the mouse models, human thymic implant vs. mouse thy-
mus or due to the different immunodeficient mice used,
NOD/SCID vs Rag-/-γc
-/-? The consensus of the investiga-
tors was that there is no clear-cut best rodent model that
is applicable to all studies and specific models may be
more suited for investigating different aspects of HIV
pathogenesis and therapeutic efficacy. For this purpose it
is advisable to continue to fund the development of new
rodent model systems.
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